China Universal Asset Management Company’s Larimar Therapeutics LRMR Stock Holding History

China Universal Asset Management Company’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.4K	Sell	16,533 -2,737	-14%	-$10.9K	﹤0.01%	461
2026 Q1	$86.7K	Buy	19,270 +5,323	+38%	+$21.3K	0.01%	420
2025 Q4	$53.1K	Sell	13,947 -1,056	-7%	-$4.11K	﹤0.01%	446
2025 Q3	$48.5K	Buy	15,003 +2,143	+17%	+$8.04K	﹤0.01%	433
2025 Q2	$37.2K	Buy	12,860 +61	+0.5%	+$141	﹤0.01%	435
2025 Q1	$27.5K	Sell	12,799 -730	-5%	-$2.31K	﹤0.01%	448
2024 Q4	$52.4K	Buy	+13,529	New	+$89.3K	﹤0.01%	449
2022 Q4	–	Sell	-165	Closed	-$1K	–	429
2022 Q3	$1K	Buy	+165	New	+$413	﹤0.01%	400

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

China Universal Asset Management Company's LRMR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Larimar Therapeutics (LRMR) stake by 14% in Q2 2026, selling an estimated $10.9K and leaving 16,533 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #461.

China Universal Asset Management Company first reported a position in LRMR in Q3 2022 and has held it in 8 quarters since. The position peaked at $86.7K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

China Universal Asset Management Company held 16,533 shares of Larimar Therapeutics worth $50.4K as of Q2 2026.
China Universal Asset Management Company sold 2,737 Larimar Therapeutics shares in Q2 2026, an estimated $10.9K.
Larimar Therapeutics made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #461 holding.
China Universal Asset Management Company first reported a position in Larimar Therapeutics in Q3 2022 and has held it in 8 quarters since.
China Universal Asset Management Company's Larimar Therapeutics position peaked at $86.7K in Q1 2026.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.